PMID: 11606031Oct 19, 2001Paper

Administration of mu-, kappa- or delta2-receptor agonists via osmotic minipumps suppresses murine splenic antibody responses

International Immunopharmacology
Rahil T RahimT K Eisenstein

Abstract

Previously, our laboratory has shown that morphine given by implantation of a 75-mg slow-release pellet for 48 h suppresses murine splenic antibody responses to sheep red blood cells (SRBCs) in a plaque-forming cell (PFC) assay. However, the use of slow-release pellets for such studies is limited, as these pellets are only available in fixed doses and similar pellets for kappa and delta agonists have not been developed. In the present study, we investigated the feasibility of administering opioids via Alzet osmotic minipumps to assess their immunomodulatory effects. Groups of mice received minipumps dispensing morphine sulfate, which has primary activity at the mu opioid receptor; U50,488H, which is a kappa-selective agonist; deltorphin II, which is a delta2-selective agonist; or DPDPE, which has greater selectivity for delta1 than delta, receptors. Morphine, U50,488H and deltorphin II were all immunosuppressive, with biphasic dose-response curves exhibiting maximal (approximately 50%) suppression of the PFC response at doses of 0.5 to 2 mg/kg/day 48 h after pump implantation. Further, immunosuppression by morphine sulfate, U50,488H or deltorphin II was blocked by simultaneous implantation of a minipump administering the opioid...Continue Reading

References

Nov 2, 1992·European Journal of Pharmacology·J M BidlackD M Lawrence
Jan 1, 1992·Immunopharmacology and Immunotoxicology·J L BussiereT K Eisenstein
Jan 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·D D TaubT J Rogers
Sep 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·Y ShavitJ C Liebeskind
Apr 27, 1988·European Journal of Pharmacology·H U BryantJ W Holaday
Jan 1, 1988·Journal of Neuroscience Research·P M Dougherty, N Dafny
Oct 5, 1987·Life Sciences·H U BryantJ W Holaday
Sep 1, 1967·The Journal of Experimental Medicine·R I Mishell, R W Dutton
Jan 1, 1981·Pharmacology, Biochemistry, and Behavior·R SchulzA Herz
Sep 9, 1982·Brain Research·Z Wiesenfeld, L L Gustafsson
May 1, 1995·Anesthesiology·A Duttaroy, B C Yoburn
Apr 11, 1994·Brain Research·H N BhargavaR V House
Mar 1, 1994·International Journal of Immunopharmacology·R U ChukwuochaS Tokuda
Jan 1, 1996·Critical Reviews in Immunology·G B StefanoM H Makman
Jul 4, 1997·Drug and Alcohol Dependence·J P WestL A Dykstra
Dec 31, 1997·Journal of Neuroimmunology·M E HilburgerT K Eisenstein
Jun 4, 1998·Journal of Neuroimmunology·T K Eisenstein, M E Hilburger
Jun 4, 1998·Journal of Neuroimmunology·B M SharpJ M Bidlack
Jun 4, 1998·Journal of Neuroimmunology·J J MaddenD Ketelsen
Jun 4, 1998·Journal of Neuroimmunology·P K PetersonC C Chao

❮ Previous
Next ❯

Citations

Jan 27, 2011·Cancer Metastasis Reviews·Banafsheh AfsharimaniMarie-Odile Parat
Nov 28, 2007·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Toby K EisensteinJoseph J Meissler
Nov 28, 2007·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Prati Pal Singh, Priya Singal
Feb 2, 2010·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Benito AntonToby K Eisenstein
Jun 5, 2003·Toxicon : Official Journal of the International Society on Toxinology·S C SampaioY Cury
Jan 22, 2003·Peptides·Richard J Bodnar, Maria M Hadjimarkou
Mar 6, 2009·Gene Therapy·K N Westlund
Jun 15, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ying LuKarin N Westlund
Apr 15, 2003·Clinical Microbiology Reviews·Herman FriedmanThomas W Klein
May 8, 2013·Psychopharmacology·Richard M van RijnJennifer L Whistler
Jun 15, 2007·Journal of Neuroimmunology·Christine BörnerJürgen Kraus
May 26, 2005·International Immunopharmacology·Diana Caballero-HernándezRicardo Gomez-Flores
Jun 14, 2006·American Journal of Surgery·Martin G SchwachaLoring W Rue
Feb 26, 2008·Brain, Behavior, and Immunity·Paola SacerdoteLorenzo Somaini
Jul 29, 2006·FEMS Immunology and Medical Microbiology·Herman FriedmanThomas W Klein
Mar 2, 2018·Chemistry : a European Journal·Sebastian LipsSiegfried R Waldvogel
Jun 23, 2006·Anesthesia and Analgesia·Craig CharlestonEd W Childs
Jan 30, 2008·Anesthesia and Analgesia·Rudolph PuanaEd W Childs
May 1, 2007·Plant Disease·Martin I ChilversTobin L Peever
Apr 29, 2014·Bulletin of Experimental Biology and Medicine·M A CheidoE N Zhukova
Jan 11, 2020·Frontiers in Immunology·Toby K Eisenstein

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.